How Weisblum was paid
$521,750 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Other | Total |
|---|---|---|---|---|
| Eric WeisblumChief Executive Officer | $350,000 | $83,782 | $87,968 | $521,750 |
| Daniel RyweckChief Financial Officer | $60,000 | $20,946 | $28,548 | $101,494 |
What changed and why
- $522K$521,750 was Eric Weisblum’s 2025 total compensation, down from $630,051 in 2024.
- $83,782$83,782 in option awards represented Weisblum’s only reported equity compensation in 2025.
- 13,333 incentive stock options were granted to Weisblum on May 23, 2025, vesting on May 23, 2026.
- $101K$101,494 was Daniel Ryweck’s 2025 total compensation, including $20,946 in option awards.
- $700K$700,000 is Weisblum’s stated potential termination payment based on 24 months of current base salary.
- 44,394 shares were added to the equity plan’s available share reserve on January 1, 2026.
Other Silo Pharma proxy statements
- 2025 proxy statement
Eric Weisblum paid $630,051 (+11% on the year).
Filed Sep 05, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.